For the best experience on the Abcam website please upgrade to a modern browser such as Google Chrome

Hello. We're improving abcam.com and we'd welcome your feedback.

Hello. We're improving abcam.com and we'd welcome your feedback.

Infomation icon

We haven't added this to the BETA yet

New BETA website

New BETA website

Hello. We're improving abcam.com and we'd welcome your feedback.

Take a look at our BETA site and see what we’ve done so far.

Switch on our new BETA site

Now available

Search and browse selected products

  • A selection of primary antibodies

Purchase these through your usual distributor

In the coming months

  • Additional product types
  • Supporting content
  • Sign in to your account
  • Purchase online
United States
Your country/region is currently set to:

If incorrect, please enter your country/region into the box below, to view site information related to your country/region.

Call (888) 77-ABCAM (22226) or contact us
Need help? Contact us

  • My account
  • Sign out
Sign in or Register with us

Welcome

Sign in or

Don't have an account?

Register with us
My basket
Quick order
Abcam homepage

  • Research Products
    By product type
    Primary antibodies
    Secondary antibodies
    ELISA and Matched Antibody Pair Kits
    Cell and tissue imaging tools
    Cellular and biochemical assays
    Proteins and Peptides
    By product type
    Proteomics tools
    Agonists, activators, antagonists and inhibitors
    Cell lines and Lysates
    Multiplex miRNA assays
    Multiplex Assays
    By research area
    Cancer
    Cardiovascular
    Cell Biology
    Epigenetics
    Metabolism
    Developmental Biology
    By research area
    Immunology
    Microbiology
    Neuroscience
    Signal Transduction
    Stem Cells
  • Customized Products & Partnerships
    Customized Products & Partnerships

    Customized products and commercial partnerships to accelerate your diagnostic and therapeutic programs.

    Customized products

    Partner with us

  • Support
    Support hub

    Access advice and support for any research roadblock

    View support hub

    Protocols

    Your experiments laid out step by step

    View protocols

  • Events
    • Conference calendar
    • Cancer
    • Cardiovascular
    • Epigenetics & Nuclear signaling
    • Immunology
    • Neuroscience
    • Stem cells
    • Tradeshows
    • Scientific webinars
    Keep up to date with the latest events

    Full event breakdown with abstracts, speakers, registration and more

    View global event calendar

  • Pathways
    Cell signalling pathways

    View all pathways

    View all interactive pathways

Explore the power of knock-out cell lines for your research

Therapy Discovery for Age-Related Immune System Dysregulation Using the FirePlex®-384 Multiplex Immunoassay

Related

  • Multiplex assays
    • FirePlex immunoassays
      • FirePlex-96 assays
        • FirePlex-384 and FirePlex-1536
        • FirePlex miRNA assays
          • Enabling Biomarker Discovery and Screening with FirePlex® webinar
            • Biomarker profiling in drug discovery and clinical applications webinar
              • FirePlex Multiplex Immunoassay for Discovery of Neuroinflammatory Biomarkers webinar

                Join Will Van Trump (Spring Discovery), Delia Bucher (Assay.Works), and Paul Wylie (Abcam) to hear how FirePlex-384 multiplex immunoassay can accelerate high-throughput screening and help identify candidate compounds in early drug discovery. 

                Published May 27, 2021

                High-throughput screening (HTS) technologies play an important role in drug discovery and development. Combining HTS with multiplexing is valuable but technically challenging. FirePlex® multiplex assay technology combines these two features. FirePlex is based on fluorescent dye encoded micro-particles and a powerful decoding workbench software. The assay platform has been adapted to interface with laboratory automation to allow multiplexing and absolute quantification of up to 10 protein analytes in a 384-well plate format. 

                In this webinar, you will hear from Assay.Works, a CRO, and Spring Discovery, a biopharma company, on their recent collaboration. Their goal was to profile the differences between viral responses of old and young immune cells and identify rejuvenating drugs to improve viral defense mechanisms. The study focused on why COVID-19 infection causes different responses in young and elderly patients and identified compounds able to improve viral defense mechanisms.

                This study required a multiplexing approach to analyze cytokines with a robust and sensitive assay in an automated workflow, which doesn't need new equipment. You'll learn how integrating Abcam's FirePlex-384 multiplex immunoassay into the discovery platform supported Spring Discovery and Assay.Works in identifying candidate compounds.

                Webinar objectives:

                • Learn about the FirePlex assay technology, including the assay principle, assay workflow, and technical specifications
                • Understand the advantages of using multiplex assay technologies in early drug discovery
                • See how the features of the FirePlex assay technology make it uniquely suitable for high-throughput screening and early drug discovery
                • Learn about Spring Discovery and its unique approach and discovery platform
                • Find out how the FirePlex assay technology helped Spring Discovery in its screening efforts
                • Learn about Assay.Works and the services it provides


                Who would be interested in this webinar?

                • Drug discovery scientists
                • Researchers interested in multiplex assays
                • Cell-based assay developers
                • Laboratory auto

                About Assay.Works and Spring Discovery

                Assay.Works is a contract research organization (CRO) specializing in assay services for pharmaceutical, biotech, and academic research. Assay. Works' mission is to accelerate their partner's research programs by developing and executing predictive and scalable assays to quantify the bioactivity of novel chemical and biological entities. In addition to FirePlex service, Assay. Works' service portfolio includes Assay Development, High-Throughput Screening (HTS), Cell Lines, Bioactivity Assessments, Quantitative Biology Applications.

                Spring Discovery seeks to discover small molecule compounds that can rejuvenate the immune system. Spring Discovery's platform combines data generated from multiplex profiling of secreted factors using the FirePlex assay with multi-parametric high-content imaging to identify a suite of phenotypic features capable of distinguishing in vitro older versus younger immune cells. These phenotypic features were utilized to devise an immune-cell age score, which was then used to rank compounds for their potential to serve as age-related therapies.


                About the presenters

                Will Van Trump, PhD, Lead Process Engineer, Spring Discovery
                Will is the Lead Process Engineer at Spring Discovery, responsible for assay development and process scale-up. He has a decade of experience in process and automation engineering in the biotech space, serving as the Manager of Process Engineering at Myriad Women's Health, the Director of Process Engineering at EpiBiome, and Senior Manager of Engineering at Illumina. Before moving into the biotech industry, Will obtained his Doctorate in Biology from the University of California at Irvine in the Department of Ecology and Evolution, where he studied the sensory biomechanics of the lateral line sensory system in zebrafish.

                Delia Bucher, PhD, Scientist, Assay.Works

                Delia Bucher is an experienced biologist specialized in the fields of cell biology and microscopy. She joined the Assay.Works team in 2019 as a scientist for assay development and high-throughput screening. She focuses on cell-based high-content screening and multiplex assays. In this context, she established the FirePlex high-throughput immunoassays at Assay.Works to combine imaging data with the quantification of up to 10 secreted analytes in a 384-well format.

                Paul Wylie, PhD, Director of Multiplex, Kits and Assays, Abcam

                Paul has over 20 years of experience working in life sciences, focusing on delivering early drug discovery research solutions, particularly in HTS, using phenotypic screening and other multiplexed techniques. He is now the Director of Multiplex at Abcam, responsible for leading the strategy and implementation of Abcam's multiplex portfolio.

                Learn more about FirePlex-384


                Get resources and offers direct to your inbox Sign up
                A-Z by research area
                • Cancer
                • Cardiovascular
                • Cell biology
                • Developmental biology
                • Epigenetics & Nuclear signaling
                • Immunology
                • Metabolism
                • Microbiology
                • Neuroscience
                • Signal transduction
                • Stem cells
                A-Z by product type
                • Primary antibodies
                • Secondary antibodies
                • Biochemicals
                • Isotype controls
                • Flow cytometry multi-color selector
                • Kits
                • Loading controls
                • Lysates
                • Peptides
                • Proteins
                • Slides
                • Tags and cell markers
                • Tools & Reagents
                Help & support
                • Support
                • Make an Inquiry
                • Protocols & troubleshooting
                • Placing an order
                • RabMAb products
                • Biochemical product FAQs
                • Training
                • Browse by Target
                Company
                • Corporate site
                • Investor relations
                • Company news
                • Careers
                • About us
                • Blog
                Events
                • Tradeshows
                • Conferences
                International websites
                • abcam.cn
                • abcam.co.jp

                Join with us

                • LinkedIn
                • facebook
                • Twitter
                • YouTube
                • Terms of sale
                • Website terms of use
                • Cookie policy
                • Privacy policy
                • Legal
                • Modern slavery statement
                © 1998-2022 Abcam plc. All rights reserved.